Acetazolamide for the Prevention of Acute Mountain Sickness-A Systematic Review and Meta-analysis

Journal of Travel Medicine

Volumn 19, Issue 5, 2012, Pages 298-307

  Ritchie, Neil D ^a   Baggott, Amy V ^b   Andrew Todd, W T ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MONKLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; PLACEBO;

ACUTE DISEASE; ALTITUDE DISEASE; COCHRANE LIBRARY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSGEUSIA; EMBASE; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; URINARY FREQUENCY;

ACCLIMATIZATION; ACETAZOLAMIDE; ACUTE DISEASE; ALTITUDE SICKNESS; AMINES; BRAIN EDEMA; CARBONIC ANHYDRASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOUNTAINEERING; PULMONARY EDEMA; TREATMENT OUTCOME;

EID: 84865858098     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2012.00629.x     Document Type: Review

References (54)

1. Imray C, Booth A, Wright A, Bradwell A,. Acute altitude illnesses. BMJ 2011; 343: d4943.
2. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society Consensus Guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21: 146-155.
3. Hillebrandt D,. Wilderness Medical Society Consensus Guidelines for the prevention and treatment of acute altitude illness-a view from the other side of the Atlantic. Wilderness Environ Med 2010; 21: 383-384.
4. Ried LD, Carter KA, Ellsworth A,. Acetazolamide or dexamethasone for prevention of acute mountain sickness: a meta-analysis. J Wilderness Med 1994; 5: 34-48. (Pubitemid 24156615)
5. Dumont L, Mardirosoff C, Tramèr M,. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000; 321: 267-272. (Pubitemid 30487464)
6. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
7. Utz G, Schlierf G, Barth P, et al. Prevention of acute mountain sickness using acetazolamide. Munch Med Wochenschr 1970; 112: 1122-1124.
8. Kayser B, Hulsebosch R, Bosch F,. Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alt Med Biol 2008; 9: 15-23. (Pubitemid 351363932)
9. Vuyk J, Van Den Bos J, Terhell K, et al. Acetazolamide improves cerebral oxygenation during exercise at high altitude. High Alt Med Biol 2006; 7: 290-301. (Pubitemid 46099761)
10. Carlsten C, Swenson ER, Ruoss S,. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol 2004; 5: 33-39. (Pubitemid 38455803)
11. Wright AD, Beazley MF, Bradwell AR, et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness Environ Med 2004; 15: 25-31. (Pubitemid 38326086)
12. Mirrakhlmov M, Brimkulov N, Cieslicki J, et al. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma. Eur Respir J 1993; 6: 536-540. (Pubitemid 23135192)
13. Nicholson A, Smith P, Stone B, et al. Altitude insomnia: studies during an expedition to the Himalayas. Sleep 1988; 11: 354-361.
14. Jain S, Singh M, Sharma V, et al. Amelioration of acute mountain sickness: comparative study of acetazolamide and spironolactone. Int J Biometeorol 1986; 30: 293-300. (Pubitemid 17000405)
15. McIntosh I, Prescott R,. Acetazolamide in prevention of acute mountain sickness. J Int Med Res 1986; 14: 285-287. (Pubitemid 16031235)
16. Greene M, Kerr A, McIntosh I, Prescott R,. Acetazolamide in prevention of acute mountain sickness: a double-blind controlled cross-over study. BMJ 1981; 283: 811-813. (Pubitemid 11000266)
17. Birmingham Medical Research Expeditionary Society Mountain Sickness Study Group. Acetazolamide in control of acute mountain sickness. Lancet 1981; 317: 180-183.
18. Evans W, Robinson S, Horstman D, et al. Amelioration of the symptoms of acute mountain sickness by staging and acetazolamide. Aviat Space Environ Med 1976; 47: 512-516.
19. Forwand SA, Landowne M, Follansbee JN, Hansen JE,. Effect of acetazolamide on acute mountain sickness. N Engl J Med 1968; 279: 839-845.
20. Cain S, Dunn J,. Low doses of acetazolamide to aid accommodation of men to altitude. J Appl Physiol 1966; 21: 1195-1200.
21. Banderet LE,. Self-rated moods of humans at 4300 m pretreated with placebo or acetazolamide plus staging. Aviat Space Environ Med 1977; 48: 19-22. (Pubitemid 8032048)
22. Fletcher RF, Wright AD, Jones GT, Bradwell AR,. The clinical assessment of acute mountain sickness. Q J Med 1985; 54: 91-100. (Pubitemid 15134932)
23. Bradwell AR, Dykes PW, Coote JH, et al. Effect of acetazolamide on exercise performance and muscle mass at high altitude. Lancet 1986; 327: 1001-1005. (Pubitemid 16102968)
24. White AJ,. Cognitive impairment of acute mountain sickness and acetazolamide. Aviat Space Environ Med 1984; 55: 598-603. (Pubitemid 14055619)
25. Gray GW, Bryan AC, Frayser R, et al. Control of acute mountain sickness. Aerosp Med 1971; 42: 81-84.
26. Kronenberg R, Cain S. Effects of acetazolamide on physiologic and subjective responses of men to 14,000 feet. Tech Rep SAM-TR 1967:1-10.
27. Basnyat B, Holck PS, Pun M, et al. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group). Wilderness Environ Med 2011; 22: 15-22.
28. Subudhi AW, Dimmen AC, Julian CG, et al. Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. J Appl Physiol 2011; 110: 1219-1225.
29. Gertsch JH, Lipman GS, Holck PS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med 2010; 21: 236-243.
30. Basnyat B, Hargrove J, Holck PS, et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol 2008; 9: 209-216.
31. vanPatot MCT, Leadbetter G III, Keyes LE, et al. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol 2008; 9: 289-293.
32. Moraga FA, Flores A, Serra J, et al. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med 2007; 18: 251-257.
33. Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 2006; 7: 17-27.
34. Hillenbrand P, Pahari AK, Soon Y, et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial. Wilderness Environ Med 2006; 17: 87-93. (Pubitemid 43902276)
35. Chow T,. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165: 296-301. (Pubitemid 40216282)
36. Gertsch JH,. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 2004; 328: 797.
37. Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol 2003; 4: 45-52. (Pubitemid 36511798)
38. Hussain M, Aslam M, Khan Z,. Acute mountain sickness score and hypoxemia. J Pak Med Assoc 2001; 51: 173-179. (Pubitemid 32607048)
39. Ellsworth A, Meyer E, Larson E,. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991; 154: 289-293.
40. Zell SC, Goodman PH,. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med 1988; 148: 541-545.
41. Ellsworth A, Larson E, Strickland D,. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 1987; 83: 1024-1030. (Pubitemid 18098873)
42. Larson E, Roach R, Schoene R, Hornbein T,. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 1982; 248: 328-332. (Pubitemid 12070767)
43. Hackett P, Rennie D, Levine H,. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976; 308: 1149-1155.
44. Roach RC, Bartsch P, Hackett P, Oelz O,. The Lake Louise acute mountain sickness scoring system. In:, Sutton J, Coates G, Huston C, eds. Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium, 9-13 February 1993; Lake Louise, Alberta, Canada. Burlington, VT: Queen City Printers, 1993: 272-274.
45. Sampson JB, Kobrick JL,. The environmental symptoms questionnaire: revisions and new filed data. Aviat Space Environ Med 1980; 51: 872-877. (Pubitemid 11109159)
46. Stamper DA, Sterner RT, Kinsman RA,. Symptomatology subscales for the measurement of acute mountain sickness. Percept Mot Skills 1971; 33: 735-742.
47. Seupaul RA, Welch JL, Malka ST, Emmett TW. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Annals of Emergency Medicine 2011. [Epub ahead of print http://dx.doi.org/10.1016/j.annemergmed. 2011.10.015]
48. Savourey G, Guinet A, Besnard Y, et al. Evaluation of the Lake Louise acute mountain sickness scoring system in a hypobaric chamber. Aviat Space Environ Med 1995; 66: 963-967.
49. Dellasanta P, Gaillard S, Loutan L, Kayser B,. Comparing questionnaires for the assessment of acute mountain sickness. High Alt Med Biol 2007; 8: 184-191. (Pubitemid 47403501)
50. Shah NM, Windsor JS, Meijer H, Hillebrandt D,. Are UK commercial expeditions complying with wilderness medical society guidelines on ascent rates to altitude? J Travel Med 2011; 18: 214-216.
51. Jackson SJ, Varley J, Sellers C, et al. Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Alt Med Biol 2010; 11: 217-222.
52. Davies AJ, Kalson NS, Stokes S, et al. Determinants of summiting success and acute mountain sickness on Mt Kilimanjaro (5895 m). Wilderness Environ Med 2009; 20: 311-317.
53. Croughs M, Van Gompel A, Van den Ende J,. Acute mountain sickness in travelers who consulted a pre-travel clinic. J Travel Med 2011; 18: 337-343.
54. Kelly TE, Hackett PH,. Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol 2010; 11: 319-323.